Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Alligator Bioscience AB ( (SE:ATORX) ) has provided an announcement.
Alligator Bioscience will publish its full-year 2025 report on 12 February 2026 and on the same day host an English-language webinar and conference call for investors, analysts and media, led by CEO Søren Bregenholt and CFO Johan Giléus. The event, which requires advance registration and will include a Q&A session, underlines the company’s effort to engage the capital markets around its financial performance and development progress, with the full report to be made available on its website upon release.
The most recent analyst rating on (SE:ATORX) stock is a Sell with a SEK0.18 price target. To see the full list of analyst forecasts on Alligator Bioscience AB stock, see the SE:ATORX Stock Forecast page.
More about Alligator Bioscience AB
Alligator Bioscience is a clinical-stage biotechnology company specializing in tumor-directed antibody drugs, with a focus on the CD40 receptor as an immuno-oncology target to prime T cells and counteract tumor-induced immunosuppression. Its lead candidate, mitazalimab, is ready for Phase 3 development and has delivered strong 24‑month follow-up survival data in metastatic pancreatic cancer, positioning the Nasdaq Stockholm-listed firm as an emerging player in cancer therapeutics from its base in Lund, Sweden.
Average Trading Volume: 4,935,588
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK87.04M
For a thorough assessment of ATORX stock, go to TipRanks’ Stock Analysis page.